ImmunoGen, Inc. Strikes $200.5 Million License Pact With Eli Lilly and Company
Published: Aug 30, 2013
On August 26, 2013, ImmunoGen, Inc. (Nadaq: IMGN) entered into a license agreement with Eli Lilly and Company (NYSE: LLY) granting Lilly rights to use our maytansinoid-based Targeted Antibody Payload (TAP) technology to develop and commercialize products directed to a specific antigen target on an exclusive basis. This license was granted pursuant to the terms of an existing Multi-Target Agreement entered into by the Company and Lilly in 2011.
Help employers find you! Check out all the jobs and post your resume.